RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its 2010
third quarter (Q3) financial results.


Total Sales were 33% higher at $1,216,019 in the first nine months of 2010
compared to $911,543 in the corresponding previous year period. The sales in Q3
2010 were also 14% higher at $616,964 compared to $540,870 in Q3 2009. Gross
Margins increased from 64.7% in the first nine months of 2009, to 72.8% in the
first nine months of 2010.


The Company incurred a loss of ($31,987) in the first nine months of 2010, 64%
lower than a loss of ($90,146) in the first nine months of 2009. During the
quarter, the Company incurred one time costs of $57,354 on account of a June
2010 product recall of one of its products.


Full details of 2010 third quarter results including September 30, 2010
Financial Statements and Management's Discussion & Analysis will be posted on
sedar.com on November 23, 2010.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024